The authors stated that PET scans might be useful for predicting long-term benefits and for guiding the discontinuation of anti-PD-1-based immunotherapy among metastatic melanoma patients after one year of treatment [17]. This evidence concerns the gene PDCD1 and metastatic melanoma.